Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (DE:1NE)
FRANKFURT:1NE
RESEARCH TOOLSreports
Holding DE:1NE?
Track your performance easily
1NE Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.64 - €8.72
Previous Close€0.72
Volume0.00
Average Volume (3M)188.00
Market Cap
€43.12M
Enterprise Value€65.86M
Total Cash (Recent Filing)$23.00M
Total Debt (Recent Filing)$47.11M
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Feb 27, 2025EPS Estimate
-€0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding45,600,795
10 Day Avg. Volume0
30 Day Avg. Volume188
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-1.10
Price to Sales (P/S)4.41
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.15
Enterprise Value/Gross Profit15.04
Enterprise Value/Ebitda-1.23
Forecast
1Y Price Target
€3.34Price Target Upside364.26% Upside
Rating ConsensusHold
Number of Analyst Covering5
Verrica Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceThe VP-315 showed compelling open-label proof of concept data including a 51% clearance rate and over 70% residual carcinoma tumor size reduction.
Market DemandThere appears to be increasing demand in Q3, with 7,706 applicators dispensed, a 29% increase compared to Q2.
Strategic ManagementNew management is pinpointing and removing hurdles for commercial adoption, with a smaller salesforce focused on target practices treating high volumes of molluscum.
Bears Say
Financial Performance And DebtVRCA was unable to draw additional tranches (up to $75MM) from the debt facility after not meeting required revenue targets.
Management And Organizational ChallengesThe departure of key C-suite executives in charge of the two most important functions (commercial and financial) at VRCA in this current situation is concerning.
Product Launch And Market ChallengesThe >50% downsizing of Ycanth's promotional efforts will represent a significant headwind for a launch that had shown recent signs of struggle.
---
Options Prices
Currently, No data available
---
Ownership Overview
57.14% Insiders
7.30% Mutual Funds
18.24% Other Institutional Investors
12.76% Public Companies and
Individual Investors
1NE FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was €0.64 and its highest was €8.72 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Currently, no data Available
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 96 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on Nov 04, 2024. The company reported -€0.468 earnings per share for the quarter, missing the consensus estimate of -€0.359 by -€0.109.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -€0.29.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 45,600,796 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -€0.468 in its last earnings report, missing expectations of -€0.359. Following the earnings report the stock price went down -5.865%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Among the largest hedge funds holding Verrica Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Verrica Pharmaceuticals’s shares valued at 10M.
---
Verrica Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
€3.34 (364.26% Upside)
€3.34 (364.26% Upside)
Blogger Sentiment
Bullish
DE:1NE Sentiment 100%
Sector Average 72%
Sector Average 72%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.17%
12-Months-Change
Fundamentals
Return on Equity
-2059.89%
Trailing 12-Months
Asset Growth
-66.11%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
---
1NE Earnings Call
Q2 2024
0:00 / 0:00
---
1NE Stock 12 Month Forecast
Average Price Target
€3.34
▲(364.26% Upside)
Technical Analysis
Verrica Pharmaceuticals
―
SELLAS Life Sciences Group
―
Evolus
―
Bioxcel Therapeutics
―
ESSA Pharma
―
Best Analysts Covering 1NE
1 Year
---